Navigation Links
Immunosyn Corporation Names Stephen Ferrone as CEO
Date:10/23/2007

LA JOLLA, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN) has announced the appointment of Stephen D. Ferrone as the company's Chief Executive Officer, President and board member.

"I am honored to step into this leadership role at Immunosyn and help shape the company's success. I believe we have the potential to improve the quality of life for millions of people who suffer from painful and debilitating diseases," says Ferrone.

Ferrone is a veteran marketing and sales executive with demonstrated national leadership of strategic and tactical initiatives. His extensive career includes nine years of service with ABN AMRO Asset Management and its Investment Funds Services Group as genesis architect of its marketing strategy.

Ferrone is a graduate of Northwestern University and Loyola School of Law and began his professional career in Chicago, Illinois as a felony trial prosecutor for Cook County. He then transitioned to the wealth management industry and became the Regional Marketing Director at Schwab Institutional and the National Sales Director for ABN AMRO, where he set the strategic marketing plan and raised new investment sales of over $9 billion dollars over his nine-year tenure. Recently, Ferrone provided strategic consulting services to the financial and biotech industries where he became associated with the principals of Argyll Biotechnologies.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
2. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
3. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
4. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
5. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
6. Health Minister Wants Names of Uncooperative Hospital Consultants
7. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
8. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
9. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
10. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett is ... these scholarships is to encourage applicants to pursue a degree in their field of ... parishes. , “We have available jobs in St. Landry and Evangeline Parishes that ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... cycle of pharmaceutical products, garnering increased attention from all stakeholders in the development ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... announced that nominations have closed for the ISE Southeast Awards 2016. Finalists and ... announced at the ISE® Southeast Executive Forum and Awards Gala on March 15, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO Kenneth Fisher ... Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare ... System. This will be the first Fisher House in Nevada, and will provide ...
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new partnership in ... latest campaign focuses on the fight against breast cancer, fundraising for a local woman ... here . , Carmen is a loving single mother of two boys who also ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Stem cells are primitive cells found in all multi-cellular ... to differentiate into mature cell types Stem cells are ... embryonic stem cells were derived from embryos in 1981, ... culturing of embryonic stem cells from non-human primates occurred ... As a result of these discoveries, stem cells can ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
(Date:2/11/2016)...   Health 2.0 , the premiere showcase and ... today " 10 Year Global Retrospective ", a platform ... past ten years.   --> ... has served as the preeminent thought-leader in the health ... technologies, companies, innovators, and patient-activists through an array of ...
Breaking Medicine Technology: